Browse Categories

Publications by authors named "Robert F O'Brien"

  • Page 1 of 1
Functional comparison of recombinant acidic mammalian chitinase with enzyme from murine bronchoalveolar lavage.
Eric R Goedken Robert F O'Brien Tao Xiang David L Banach Susan C Marchie

Protein Expr Purif

January 2011

Acidic mammalian chitinase (AMCase) is an enzyme that selectively degrades the biopolymer chitin. Several chitinase enzymes are utilized by mammals to hydrolyze chitin encountered by inhalation and ingestion. AMCase is distinct from other mammalian chitinases as its activity is retained in strongly acidic conditions (pH <2.

View Article and Find Full Text PDF

Synopsis of recent research by authors named "Robert F O'Brien"

  • - Robert F O'Brien's research primarily focuses on the efficacy of immunotherapy, specifically on the use of pembrolizumab in treating advanced non-small-cell lung cancer (NSCLC) with high PD-L1 expression.
  • - His pivotal study, published in November 2016, compared pembrolizumab to traditional chemotherapy in previously untreated patients, demonstrating a significant improvement in treatment outcomes for those using the immunotherapy.
  • - The findings from this phase 3 trial support the potential of pembrolizumab as a first-line treatment option, particularly for patients with a specific expression of PD-L1, highlighting a shift toward personalized cancer therapies in clinical practice.

Privacy Policy Site Map

© LitMetric 2024. All rights reserved.